Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.
Ruxolitinib phosphate (INCB-018424) is under development for the treatment of prurigo nodularis (PN), graft versus host disease, discoid lupus erythematosus, vitiligo and atopic dermatitis, hand ...